Share price · KNSA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KNSA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 27 Oct 2026+22.2%
- 26 Oct 2026-4.9%
Nothing announced by KNSA that day or the session before.
- 23 Oct 2026-5.0%
- 28 Jul 2026+25.0%
- 28 Apr 2026+23.5%
Nothing announced by KNSA that day or the session before.
- 20 Apr 2026-5.4%
Nothing announced by KNSA that day or the session before.
- 8 Apr 2026-3.9%
Nothing announced by KNSA that day or the session before.
- 24 Feb 2026-8.2%
Nothing announced by KNSA that day or the session before.
- 19 Feb 2026+3.9%
Nothing announced by KNSA that day or the session before.
- 16 Jan 2026+3.9%
Nothing announced by KNSA that day or the session before.
Share of unusual movement by asset
For each asset, the share of KNSA's own-move activity since 15 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 38% |
| Sessions with no dated event | — | 62% |
No dated announcements about its assets since 15 Oct 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Oncostatin M receptor beta (OSMRβ)Monoclonal antibody | Inflammatory Bowel Disease Ulcerative Colitis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
August 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $286M | $33M | $82M+ $487M short-term inv. | —$48M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $244M | $41M | $176M+ $350M short-term inv. | —$47M operating cash flow | report ↗ |
| 2026-Q1 | $214M | $27M | $190M+ $278M short-term inv. | —$50M operating cash flow | report ↗ |
| 2025-Q3 | $181M | $24M | $175M+ $177M short-term inv. | —$34M operating cash flow | report ↗ |
| 2025-Q2 | $157M | $19M | $192M+ $116M short-term inv. | —$28M operating cash flow | report ↗ |
| 2025-Q1 | $138M | $19M | $157M+ $111M short-term inv. | —$22M operating cash flow | report ↗ |
| 2024-Q3 | $112M | $26M | $97M+ $126M short-term inv. | $13M-$2.2M operating cash flow | report ↗ |
| 2024-Q2 | $109M | $24M | $99M+ $119M short-term inv. | $3.9M$5.2M operating cash flow | report ↗ |
| 2024-Q1 | $80M | $26M | $141M+ $72M short-term inv. | $18M$4.0M operating cash flow | report ↗ |
| 2023-Q3 | $67M | $17M | $118M+ $83M short-term inv. | $14M$17M operating cash flow | report ↗ |
| 2023-Q2 | $71M | $24M | $113M+ $72M short-term inv. | —-$3.7M operating cash flow | report ↗ |
| 2023-Q1 | $48M | $15M | $81M+ $107M short-term inv. | $12M-$4.3M operating cash flow | report ↗ |
| 2022-Q3 | $99M | $16M | $176M+ $25M short-term inv. | —$62M operating cash flow | report ↗ |
| 2022-Q2 | $27M | $14M | $94M+ $44M short-term inv. | $20M-$7.8M operating cash flow | report ↗ |
| 2022-Q1 | $32M | $21M | $63M+ $82M short-term inv. | $25M-$37M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $678M | $97M | $166M+ $248M short-term inv. | —$138M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $423M | $112M | $184M+ $60M short-term inv. | $11M$26M operating cash flow | report ↗ |
| 2023-FY | $270M | $76M | $108M+ $98M short-term inv. | —$13M operating cash flow | report ↗ |
| 2022-FY | $220M | $65M | $123M+ $68M short-term inv. | —$5.8M operating cash flow | report ↗ |
| 2021-FY | $39M | $99M | $122M+ $60M short-term inv. | $39M-$126M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 87 sales ($121.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Paolini John F. · CHIEF MEDICAL OFFICER | Option exercise | 29,670 | $10.36 | $307K | Form 4 |
| 2026-11-13 | Paolini John F. · CHIEF MEDICAL OFFICER | Option exercise | 4,994 | $11.10 | $55K | Form 4 |
| 2026-11-13 | Paolini John F. · CHIEF MEDICAL OFFICER | Option exercise | 3,723 | $11.97 | $45K | Form 4 |
| 2026-11-13 | Paolini John F. · CHIEF MEDICAL OFFICER | Option exercise | 3,144 | $12.97 | $41K | Form 4 |
| 2026-11-13 | Paolini John F. · CHIEF MEDICAL OFFICER | Option exercise | 2,595 | $15.52 | $40K | Form 4 |
| 2026-11-13 | Paolini John F. · CHIEF MEDICAL OFFICER | Option exercise (derivative) | 29,670 | — | — | Form 4 |
| 2026-11-13 | Paolini John F. · CHIEF MEDICAL OFFICER | Option exercise (derivative) | 4,994 | — | — | Form 4 |
| 2026-11-13 | Paolini John F. · CHIEF MEDICAL OFFICER | Option exercise (derivative) | 3,723 | — | — | Form 4 |